|Referral date||October 2013|
|10 September 2014||
In the Appraisal Consultation Document (ACD) for the appraise of empagliflozin combination therapy for treating type 2 diabetes [ID641], the Appraisal Committee requested further analyses from the company.
Boehringer Ingelheim has indicated that new economic analyses will be submitted in response to this request. In order to allow a complete set of analyses as requested by the Committee to be produced, and for those analyses to be reviewed by the Evidence Review group, NICE has agreed an extension in timings. Therefore the second Committee Meeting has been rescheduled to 25 November 2014.
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance